Analysis of cerebrospinal fluid from people with MS led to a surprising result, one which has intriguing implications for understanding and treating progressive MS.
Patient Portal Aims to Fuel Research; MS With Other Chronic Diseases; Push for MS Cure in the News; Relapses as Adverse Events; The Language of Science
Cynthia McKelvey and Carol Cruzan Morton
Items of interest to multiple sclerosis researchers from around the Web...
Now that we’ve seen how researchers came to the conclusion that NMO differs from MS, let’s take a closer look at the current understanding of its pathogenesis
Andreas von Bubnoff
About three-quarters of NMO patients have the aquaporin-4 antibody, a number that has been steadily...
Clinical Research, Drug Development, Laboratory Research, People
Widely touted in multiple sclerosis patient communities, low-dose naltrexone does appear to improve disease scores in about half of mice with an experimentally induced version of MS. Researchers found a similar pattern of results with met-enkephalin.
Stephani Sutherland, Ph.D.
A growing subculture of MS patients and clinicians has been touting low-dose...
Clinical Research, Drug Development, Laboratory Research, Meetings